Xenon Pharmaceuticals (XENE) PT Lowered to $55 at RBC Capital
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams lowered the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $55.00 (from $58.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
